These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32840607)

  • 1. Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort.
    Vázquez-Bourgon J; Mayoral-van Son J; Gómez-Revuelta M; Juncal-Ruiz M; Ortiz-García de la Foz V; Tordesillas-Gutiérrez D; Ayesa-Arriola R; Bioque M; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2021 Jan; 24(1):1-7. PubMed ID: 32840607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern of long-term weight and metabolic changes after a first episode of psychosis: Results from a 10-year prospective follow-up of the PAFIP program for early intervention in psychosis cohort.
    Vázquez-Bourgon J; Gómez-Revuelta M; Mayoral-van Son J; Labad J; Ortiz-García de la Foz V; Setién-Suero E; Ayesa-Arriola R; Tordesillas-Gutiérrez D; Juncal-Ruiz M; Crespo-Facorro B
    Eur Psychiatry; 2022 Aug; 65(1):e48. PubMed ID: 35971658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
    Vázquez-Bourgon J; Ibáñez Alario M; Mayoral-van Son J; Gómez Revuelta M; Ayesa Arriola R; Juncal Ruiz M; Ortiz-García de la Foz V; Crespo Facorro B
    Eur Neuropsychopharmacol; 2020 Oct; 39():46-55. PubMed ID: 32891516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period.
    Gassó P; Arnaiz JA; Mas S; Lafuente A; Bioque M; Cuesta MJ; Díaz-Caneja CM; García C; Lobo A; González-Pinto A; Parellada M; Corripio I; Vieta E; Castro-Fornieles J; Mané A; Rodríguez N; Boloc D; Saiz-Ruiz J; Bernardo M;
    J Psychopharmacol; 2020 May; 34(5):514-523. PubMed ID: 32009515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of 'all-cause discontinuation' of initial oral antipsychotic medication in first episode psychosis.
    Mustafa S; Joober R; Lepage M; Iyer S; Shah J; Malla A
    Schizophr Res; 2018 Nov; 201():287-293. PubMed ID: 29706449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study.
    Vázquez-Bourgon J; Setién-Suero E; Pilar-Cuéllar F; Romero-Jiménez R; Ortiz-García de la Foz V; Castro E; Crespo-Facorro B
    J Psychopharmacol; 2019 Mar; 33(3):284-294. PubMed ID: 30702972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight and metabolic changes in early psychosis-association with daily quantification of medication exposure during the first hospitalization.
    Vochoskova K; McWhinney SR; Fialova M; Kolenic M; Spaniel F; Svancer P; Boron P; Okaji Y; Trancik P; Hajek T
    Acta Psychiatr Scand; 2023 Sep; 148(3):265-276. PubMed ID: 37528692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
    Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
    Schizophr Res; 2016 Jul; 174(1-3):120-125. PubMed ID: 27157800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances.
    Kao AC; Rojnic Kuzman M; Tiwari AK; Zivkovic MV; Chowdhury NI; Medved V; Kekin I; Zai CC; Lieberman JA; Meltzer HY; Bozina T; Bozina N; Kennedy JL; Sertic J; Müller DJ
    J Psychiatr Res; 2014 Jul; 54():36-42. PubMed ID: 24725652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort.
    Garrido-Torres N; Ruiz-Veguilla M; Olivé Mas J; Rodríguez Gangoso A; Canal-Rivero M; Juncal-Ruiz M; Gómez-Revuelta M; Ayesa-Arriola R; Crespo-Facorro B; Vázquez-Bourgon J
    Span J Psychiatry Ment Health; 2023; 16(3):175-183. PubMed ID: 38520081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
    Mustafa S; Joober R; Iyer S; Shah J; Lepage M; Malla A
    J Clin Psychiatry; 2019 Aug; 80(5):. PubMed ID: 31509359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.
    Garriga M; Fernandez-Egea E; Mallorqui A; Serrano L; Oliveira C; Parellada E; Kirkpatrick B; Vieta E; Bernardo M; Garcia-Rizo C
    J Psychiatr Res; 2019 Aug; 115():29-35. PubMed ID: 31085376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.
    Tek C; Kucukgoncu S; Guloksuz S; Woods SW; Srihari VH; Annamalai A
    Early Interv Psychiatry; 2016 Jun; 10(3):193-202. PubMed ID: 25962699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal.
    Alvarez-Jiménez M; González-Blanch C; Crespo-Facorro B; Hetrick S; Rodríguez-Sánchez JM; Pérez-Iglesias R; Vázquez-Barquero JL
    CNS Drugs; 2008; 22(7):547-62. PubMed ID: 18547125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis.
    Curtis J; Watkins A; Rosenbaum S; Teasdale S; Kalucy M; Samaras K; Ward PB
    Early Interv Psychiatry; 2016 Jun; 10(3):267-76. PubMed ID: 25721464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.